Smileyscope pioneered and patented a powerful new approach to digital therapeutics – virtual reality neuromodulation. 

Smileyscope's innovative therapeutic platform underwent rigorous clinical studies, and has changed pediatric needle practice worldwide. International vascular access guidelines now recommend Smileyscope.

Cognoa is developing digital products intended to support healthcare providers in expediting diagnosis with the goal of improving access to timely intervention for children and families, starting with autism spectrum disorder (ASD).

We are developing digital diagnostic and therapeutic products with the goal of enabling earlier and more equitable care for behavioral health conditions.

Smileyscope pioneered and patented a powerful new approach to digital therapeutics – virtual reality neuromodulation. Smileyscope's innovative therapeutic platform underwent rigorous clinical studies, and has changed pediatric needle practice worldwide. International vascular access guidelines now recommend Smileyscope. Virtual reality neuromodulation is improving patient and healthcare outcomes. Read on to see how we enhance needle experiences.

Cognoa seeks to help improve the lives and outcomes of children and their families living with behavioral health conditions. We strive to improve timely, equitable access to a diagnosis for caregivers with early concerns of developmental delay, including autism, to support opportunities for early intervention and improved outcomes for children and their families.